Open Access

Stem cell aging in adult progeria

Cell Regeneration20154:6

DOI: 10.1186/s13619-015-0021-z

Received: 18 June 2015

Accepted: 29 August 2015

Published: 3 October 2015

Abstract

Aging is considered an irreversible biological process and also a major risk factor for a spectrum of geriatric diseases. Advanced age-related decline in physiological functions, such as neurodegeneration, development of cardiovascular disease, endocrine and metabolic dysfunction, and neoplastic transformation, has become the focus in aging research. Natural aging is not regarded as a programmed process. However, accelerated aging due to inherited genetic defects in patients of progeria is programmed and resembles many aspects of natural aging. Among several premature aging syndromes, Werner syndrome (WS) and Hutchinson–Gilford progeria syndrome (HGPS) are two broadly investigated diseases. In this review, we discuss how stem cell aging in WS helps us understand the biology of aging. We also discuss briefly how the altered epigenetic landscape in aged cells can be reversed to a “juvenile” state. Lastly, we explore the potential application of the latest genomic editing technique for stem cell-based therapy and regenerative medicine in the context of aging.

Keywords

Werner syndrome Stem cells Aging WRN

Werner syndrome: clinical features, genetics, and pathogenesis

Werner syndrome (WS) was first described by Otto Werner in 1904. Patients of WS are characterized by premature aging which are clinically apparent during 20–30 years old. WS patients show abnormal physical development such as a bird-like face, short stature, and slender limbs. They also display a high-pitched voice, remarkable loss and graying of hair, and scleroderma-like skin changes. Other common clinical presentations include bilateral cataracts, type 2 diabetes mellitus, hypogonadism (with reduced fertility), skin ulcers, premature arteriosclerosis, osteoporosis, and cancer predisposition [1, 2]. Ninety percent of WS is linked to mutations on WRN, a member of the RecQ family responsible for stable genome maintenance. Owing to autosomal recessive inheritance, biallelic mutation on WRN is pathogenic. The frequency of WS is estimated to be 1 in 20,000–40,000 in Japanese population and slightly lower in the world [3, 4].

The pathogenesis of WS due to loss of the WRN protein has been well elucidated by the biochemical nature of the WRN helicase. As a multifunctional nuclear protein, WRN is an ATP-dependent 3′–>5′ helicase and exonuclease. It unwinds secondary DNA structure such as tetraplex DNA and Holliday junction and resolves stalled replication fork during DNA replication. More importantly, WRN participates in multiple DNA repair pathways such as base excision repair, non-homologous end joining, and homologous recombination [5]. In addition to DNA replication and DNA repair, WRN is also involved in telomere maintenance. Telomere replication and protection are pivotal for maintaining genome integrity and stability and also serve as an aging marker. Accelerated aging due to loss of WRN function is well explained by its biochemical functions in relation to DNA replication, repair, recombination, and telomere maintenance [6]. From a developmental point of view, progressive cell loss due to apoptosis, cell cycle arrest, or senescence in actively dividing cells may be a consequence of WRN loss. Since WS is an adult onset disease, genetic instability accumulates with age. The manifestation of premature aging phenotypes becomes apparent when accumulated DNA damages are not properly repaired and WRN-deficient cells fail to maintain their genomic integrity [7]. WS cells thus, while being diagnosed and biopsied, display a variegated translocation mosaicism in skin fibroblasts and shorter telomere length [8]. WS fibroblasts also display premature senescence and accelerated telomere loss. From the view of pathogenesis, accumulation of deleterious DNA mutations and persistence of genomic instability eventually attain a pathogenic threshold to be reflected in different phenotypes - premature aging in many of the mesenchymal cell types and acquisition of neoplasm [9].

Stem cell aging in connection with segmental progeria in Werner syndrome

Progeroid syndromes such as WS and Hutchinson–Gilford progeria syndrome (HGPS) show phenotypes of accelerated aging resembling normal aging, such as the development of bilateral cataract, aging skin, graying and loss of hair, cardiovascular disease, and osteoporosis [1]. However, they are segmental in nature, meaning that only a specific category of tissues is predominantly affected. For WS, age-related dementia and cognitive impairment are rarely reported, leading to the hypothesis that progeroid syndromes are not seemingly an accelerated mode of aging. Nevertheless, how de novo mutation in, for instance, WRN, leads to segmental aging remains to be answered. A number of models of aging have been described to explain the aging mechanisms in stem cells as well as in model animals. These models are based on the molecular pathways known to regulate longevity, reactive oxygen species (ROS) production, mitochondrial function, telomere protection, cell cycle control and senescence, protein homeostasis, and systemic inflammation [10]. In WS, specific pathways are amplified and connected to the aging program leading to accelerated but lineage-specific aging. Our discussions below focus on the telomere function and epigenetic regulation in connection with stem cell aging in progeroid syndromes.

Telomere dysfunction as a hallmark of premature aging in WS cells

The hypothesis of telomere erosion as a chronological aging marker has been well documented by many investigations linking the telomere lengths to the biological age. A population in advanced age has a shorter average telomere length than younger groups, although variations exist within each age group [11]. In telomerase-null mice, shorter telomeres are found after several generations of interbreeding. Degenerated phenotypes are observed in late-generation, telomerase-null mice. However, reconstitution of telomerase can rescue these phenotypes, suggesting the telomere length as a pathological factor for aging [12]. Telomere is not only a biological clock counting the number of cell divisions but also a protective structure for ensuring genomic integrity and stability. Specifically, the telomere is highly organized and orchestrated by telomere-binding proteins called shelterin [13]. Loss of telomeric DNA or failure of telomere protection elicits telomere dysfunction, which subsequently induces cell cycle arrest, apoptosis, or senescence [14]. Telomere dysfunction-induced cell cycle arrest in stem cells serves as a protective mechanism to prevent propagation of genetically unstable daughter cells from passing on [15]. In many adult stem cells such as mesenchymal stem cells (MSC) and muscle stem cells, telomerase activity is restricted, indicating a finite number of divisions allowed. The adult stem cell pool is kept at a balanced quiescent and proliferative state in response to signals of differentiation or regeneration. The stem cell pool is believed to exhaust with age, thus giving less regenerative potential [16]. In laboratory mice, the longest telomeres are found in stem cell compartments requiring active proliferation such as hair follicle and small intestine stem cells [16].

How the WRN-deficient progeroid stem cells become depleted remains a challenging question to answer, mainly because adult stem cells from WS are difficult to acquire. A comparison of the in vivo telomere length from a cohort of WS patients with normal individuals demonstrates accelerated telomere attrition in muscles and skins [17]. Depletion of WRN protein in normal fibroblasts also shows a similar result, leading to the hypothesis that telomere dysfunction due to WRN deficiency is the primary cause for WS pathophysiology [18]. The mouse model for WS with Wrn deletion, however, is not sufficient to recapitulate the classical features of WS in human [19]. Such species-specific difference can be ascribed to the fact that laboratory mice possess a longer telomere reserve than human. In support of this notion, Wrn knockout mice in the background of critically short telomeres (G4-G6 Terc −/− Wrn −/− ), but not in mice with normal telomeres (Terc +/− Wrn −/− ), display aging phenotypes reminiscent of human WS [20]. However, WRN may not be an essential factor for telomere replication because telomerase-immortalized WS cells can extend the telomere length without inducing telomere dysfunction and senescence [21].

The role of WRN in telomere maintenance

The WRN protein plays a diverse role in protecting genome stability through interacting with different proteins in several pathways (refer to review by Bohr et al.) [5].

The current view suggests that WRN interacts with shelterin proteins to resolve G-quadruplex and Holliday junction structures in addition to aiding repair of DNA breaks during DNA synthesis [6, 7, 22]. G-quadruplex structures are common when DNA polymerase is synthesizing the G-rich, single-stranded D-loop found at telomeres. Consistent with this notion, WRN-depleted cells show defective synthesis at the lagging strand of sister telomeres perhaps due to the failure to resolve these structures at telomeres [23]. Eventually, accelerated and progressive telomere loss is found in WS cells, particularly in adult stem cells which are required for continuously repairing damaged tissues throughout life. Using redifferentiated stem cells derived from WS induced pluripotent stem cells (iPSCs), telomere dysfunction and sister telomere loss at the lagging strand are also observed in MSC [24]. Interestingly, redifferentiated neural progenitor cells are not affected, suggesting a lineage-specific aging mechanism in relation to the telomere function. Many questions remain open as to how different adult stem cells in WS, like hematopoietic stem cell (HSC), hair follicle and dermal stem cells, muscle and cardiovascular stem cells, and even germ cells, are selectively affected by WRN loss. One possible explanation for the segmental aging mechanism in progeroid syndrome is the differential telomerase activity in various adult stem cells. Telomerase activity is detected in germ cells and adult stem cells such as neural stem cells and HSC but almost absent in MSC. Telomerase is highly expressed in embryonic stem cells and iPSC as well as in many cancers [25]. In support of this, iPSCs reprogrammed from WS fibroblasts have normal telomere length that prevent cells from entering senescence. Differentiated cells, including MSC and fibroblasts, however, become senescent prematurely whereas they can be rescued by ectopic expression of telomerase [24, 26]. Therefore, telomerase may be a factor counteracting the telomere loss/dysfunction in the absence of the WRN helicase.

Aging-associated epigenetic alterations in normal aging and progeroid syndromes

Epigenetic modifications on DNA and histones change with age and vary in different cell types, disease states (e.g., cancers), and developmental and differentiating stages [27]. Epigenetic marks that link to aging include gain of H3K4 and H4K20 trimethylation, H4K16 acetylation, and decrease in H3K9 and H3K27 trimethylation (Fig. 1a) [28]. H4K20 trimethylation is a marker for constitutive heterochromatin. Increase of H4K20 trimethylation is found in aging tissues of rats and also in patients of HGPS [29, 30]. Epigenetic changes on histone in WS are largely unknown. A recent report suggests that heterochromatin alteration, as reflected by global loss of H3K9 trimethylation and reduction of SUV39H1 (protein that trimethylates H3K9) and HP1α, is found in WRN knockout cells [31]. The group concludes heterochromatin disorganization is a potential determinant of premature aging in WRN-deficient cells.
Fig. 1

Aging-associated epigenetic changes on histone modifications. a In aged somatic and stem cells, chromatin is progressively changed. H3K4me3, H4K20me3, and H4K16ac are increased whereas H3K9me3, H3K27me3, and H3K9ac are decreased. Chromatin remodeling proteins (e.g., HP1α and NuRD) and DNA methylation are also decreased globally (not shown). Changes of chromatin structure and organization affect transcriptional activity and genomic stability related to aging. b SIRT1 and SIRT6 are important aging regulators. SIRT1 deacetylates H3K9 and H4K16 and increases H3K9me3 through SUV39H1. SIRT6 also deacetylates H3K9 at telomeric regions. Hyperacetylation of telomeric H3K9 impairs association of the WRN protein with telomeres, hence, leading to premature aging

DNA methylation is also drifted in aged cells. Globally, hypomethylation is found at various organs/cell types with advanced age, for examples, blood and dermal fibroblasts. Repetitive sequences such as Alu and LINE-1 show decreased 5mC content with age, suggesting a mechanistic link to the increased genomic instability due to the loss of global methylation [32]. However, some locus-specific regions, especially for those at CpG islands, show hypermethylation as cells age [33]. Some of the hypermethylated genes are putative tumor suppressor genes, extrapolating that epigenetic silencing is another risk factor for increased neoplastic events in elderly people. By profiling a number of WS and HGPS patients, aberrant DNA methylation profile is detected. For WS, differential methylation on CpG sites is located in genes enriched for the IKB kinase/NF-kappaB signaling and proteinaceous extracellular matrix formation [34]. These candidate genes may be involved in the phenotypic changes observed during premature aging. Interestingly, WRN itself is also controlled by epigenetic regulation. Epigenetic downregulation of the WRN gene is found in many age-related diseases, e.g., cataract and cancer [35, 36].

Unlike genetic mutations, epigenetic modifications are reversible, raising the question of whether aging and longevity can be changed if we are able to change the age-associated epigenome. A family of genes known to promote longevity are actually enzymes for epigenetic modifications. The sirtuin gene family plays a critical role in regulating aging. Among the seven mammalian sirtuin genes, SIRT1, SIRT3, and SIRT6 have been shown to improve health through regulating diverse processes [37]. Here we briefly discuss the roles of SIRT1 and SIRT6 in stem cells and aging.

As a histone deacetylase, SIRT1 not only deacetylates H4K16 and H3K9 but also regulates the histone methyl-transferase SUV39H1 during heterochromatin formation [38]. Loss of SIRT1 reduces H3K9 trimethylation and impairs localization of heterochromatin protein 1 (HP1), an epigenetic alteration associated with aging. Although Sirt1 overexpression in mice does not increase longevity, it does improve healthy aging such as wound healing and reduced incidence of cancer [39]. In another study, Sirt1 overexpression specifically in the brain extends lifespan through upregulation of Ox2r by cooperation with Nkx2-1 [40]. In addition to the epigenetic regulatory role, Sirt1 also participates in repairing DSB in response to oxidative stress and helps to combat genomic instability and age-dependent transcriptional changes [41]. The role of SIRT1 in regulation of adult stem cell aging and homeostasis is evident. SIRT1-deleted young HSCs show skewed differentiation with reduced lymphoid compartment, anemia, and expression pattern similar to aged HSCs [42]. In human MSC derived from various adult tissues, SIRT1 demonstrates a beneficial effect on long-term growth and differentiation potential [43, 44]. Because SIRT1 is able to delay premature senescence, it also plays a role in progeria. Lamin A, the mutant form causing laminopathy-based premature aging, interacts with and activates Sirt1. Such interaction is interrupted in progeroid cells, leading to prominent decline of adult stem cells in the progeria mouse model [45]. For WS, expression and localization of WRN is modulated by SIRT1 and PML [46]. SIRT1 is reported to deacetylate WRN [47]. Acetylation of the WRN protein enhances its stability by inhibiting ubiquitination [48]. SIRT1 affects translocation of the WRN protein from nucleolus to nucleoplasm when DNA repair is required [49].

SIRT6, another important member of the sirtuin family, has other unique biological functions. SIRT6 expression declines significantly in the aged brain, which is associated with increased H3K9 acetylation [50]. Decreased SIRT6 expression is also found in HGPS and senescent cells but unknown for WS cells [51]. Sirt6 knockout mice exhibit premature aging and developmental abnormalities including profound lymphopenia and metabolic defects [52]. On the other hand, overexpression of Sirt6 increases lifespan in male but not female mice. Transgenic male mice have a lower serum level of IGF1, higher level of IGF-binding protein 1, and altered phosphorylation levels of major components of IGF1 signaling [53]. Restoring SIRT6 expression in HGPS cells impedes premature senescence and formation of dysmorphic nuclei [51]. SIRT6 is a histone H3K9 deacetylase that maintains repressive telomeric chromatin. Repressive heterochromatin at telomeres is an epigenetic mechanism for silencing telomere-proximal genes, which is disrupted in the absence of SIRT6 [54]. Mechanically, SIRT6 specifically associates with telomeres where it deacetylates H3K9 which is required for stable association with WRN. SIRT6-depleted cells show telomere dysfunction with premature cellular senescence that resembles WS cells [55]. Besides the role in telomere function, SIRT6 also helps maintain genomic stability and regulates metabolic homeostasis, another two hallmarks of aging [56]. In summary, SIRT1 and SIRT6 are the most well-known Sir2 orthologs that contribute to aging partially through epigenetic regulation of the “aging” epigenome (Fig. 1b).

Reprogramming aging epigenome for regenerative medicine

The epigenetic makeup not only becomes changed with aging but also defines cell identity during development and stem cell differentiation. Research from the last decade underscores the reversibility and plasticity of changing cell fates through epigenetic reprogramming [28]. This is achieved through resetting the epigenome by transferring a differentiated somatic nucleus to enucleated egg using somatic cell nuclear transfer technique or by expressing pluripotency-associated transcription factors (OCT4, SOX2, KLF4, and c-MYC or variant combinations) [57]. Insights gained from the reprogramming experiments raise the feasibility of erasing epigenetic memories associated with aging to restore a “juvenile” state. The epigenome of iPSC, in fact, is highly similar to embryonic stem cells (ESC) and capable of generating a variety of adult stem cells with regenerative capacity [58]. Epigenetic reprogramming is achieved initially using embryonic somatic cells [59]. Subsequently, somatic cells from more aged donors can be reprogrammed as well [60]. Moreover, skin fibroblasts from progeroid syndromes including HGPS and WS can be successfully reprogrammed to iPSC [24, 26, 61, 62]. One of the exciting findings from these reprogramming experiments is the erasure of aging phenotype originally associated with premature aging in the progeroid cells, despite the presence of the disease genotypes in those cells. Interestingly, premature aging phenotypes, such as expression of progerin proteins in HGPS and telomere dysfunction in WS, reappear when reprogrammed iPSCs are differentiated to somatic and adult stem cells. These iPSC-based disease models, although limited to in vitro condition, are useful for studying the aging mechanism in different adult stem cell compartments.

Epigenetic reprogramming to iPSC is accompanied with reactivation of telomerase activity, which is generally silenced in somatic cells [63]. Telomerase reactivation is usually found in cancers and ESC. These immortal cells require telomerase to replenish eroded telomeres to support active proliferation. Therefore, the acquisition of telomerase activity during reprogramming can be regarded as a process of “rejuvenation”. Intriguingly, iPSCs not only reactivate their telomerase activity but also acquire telomeric epigenetic marks characteristic of ESC. This is demonstrated by the decreased H3K9 and H4K20 trimethylation and increased telomere recombination as compared to differentiated MEF [64]. We also found the restoration of telomere function during reprogramming in WS cells. This is accomplished by two events, the reactivation of telomerase genes and the expression of shelterin genes [24]. Telomerase activation is beneficial to WRN-deficient cells as it elongates short telomeres and prevents accelerated senescence [65]. Secondly, proper expression of shelterin genes ensures telomere capping and prevention of telomere dysfunction. In line with this notion, reprogrammed WS cells do not exhibit premature telomere loss or defective synthesis of sister telomeres at their lagging strands (these are the two important features of WS cells) nor exhibiting premature senescence [24, 26]. In HGPS cells expressing progerin, reprogramming also silences progerin expression in HGPS iPSC lines, although it is unknown whether it is related to telomerase [61].

Telomere reprogramming appears an attractive tool for reversing aging, including progeria cells [63]. However, senescence and other aging phenotypes (e.g., genomic instability, abnormal nuclear structure, defective DNA repair, and accelerated telomere loss) recur as the pluripotent cells are differentiated to adult stem cells, limiting the use of these stem cells for regenerative purpose [61]. Genomic editing may provide a solution for this purpose. Recent advancement in technologies such as TALEN and CRISPR/Cas9 facilitates precise genetic engineering for generating mutant or correcting mutant cells. A number of patient-specific iPSC lines have been successfully corrected in different disease models to restore the normal phenotypes [66]. Currently, monogenic diseases serve a good model for genetic correction, although the issues on safety and ethics have to be refined [67]. The majority of WS is monogenic with mutations found in the WRN locus [68]. Although genetic correction of WRN has not been reported in WS cells, the availability of WS iPSC makes this approach possible [24, 26]. Indeed, restoration of wild-type WRN expression would rescue the aging-associated phenotypes caused by WRN deficiency, as demonstrated by multiple studies that lentiviral/retroviral delivery WRN gene can rescue the phenotypes [18, 69, 70]. Genetic correction of WRN may not have a significant beneficial effect on iPSC and its pluripotency, since the high telomerase activity in iPSC appears to “fix” the telomere-associated problems [24]. However, restoration of wild-type WRN is beneficial to adult stem cells or differentiated somatic cells because telomerase activity is greatly reduced in these cell types, so the role of WRN for maintaining genomic integrity and stability appears critical. We foresee the prospect of utilizing corrected WS iPSC to generate transplantable adult stem cells such as MSC for therapeutic purpose. Such approach holds two advantages. One is the global erasure of aging epigenetic marks and telomere reprogramming during integration-free and safe iPSC generation. The other one is the correction of disease-causing gene in pluripotent state rather than in more differentiated cells because clonal selection and expansion require substantial cell proliferation, which is telomere-sensitive.

Recent advances in anti-aging research

Progeroid syndromes share many similarities to natural aging, despite the different causes and origins driving the aging process. Reversal of aging through epigenetic reprogramming is still technically challenging. Anti-aging research on natural aging may also help developing drugs for treating premature aging diseases (Fig. 2). For example, vitamin C is generally used as an anti-oxidant for anti-aging. Moreover, it is shown to change the aging signaling pathway and improve healthy aging in the liver of a mouse model for WS [71]. Interestingly, the role of vitamin C is more than merely an anti-oxidant. It is surprisingly found to boost reprogramming of somatic cells to iPSC by alleviating senescence [72]. Vitamin C is later known to reduce the epigenetic barrier through regulating histone demethylases Jhdm1a/1b and DNA demethylation-related enzyme Tet1; both classes are critical epigenetic enzymes for reprogramming and senescence [73, 74]. The beneficial effect of vitamin C thus is not only limited to its anti-oxidation activity but also its ability to reset the aging-associated epigenetic marks. Adult WS patients mostly develop type 2 diabetes mellitus. Antidiabetic drugs like metformin, biguanide, and thiazolidinediones have been reported to improve insulin sensitivity in WS patients [7577]. In addition to improve diabetes, metformin plays a second role in extending lifespan, as shown in animal models and clinical trials [78, 79]. Resveratrol, a natural product for anti-aging research, is also shown to improve insulin-resistant hyperglycemia and fatty liver in Wrn mutant mice, although with undesired side effects such as increased frequency of lymphoma and solid tumors [80]. Small molecules such as the SB203580 compound that inhibits the p38 MAPK signaling can ameliorate premature senescence in WS fibroblasts [81]. Such inhibitors are still in clinical trials. A number of anti-aging approaches have been recently discovered to improve healthy aging. These approaches, though they have not been experimentally and clinically tested for WS, may have therapeutic benefit on progeroid syndromes. For instance, age-related mitochondrial dysfunction (another hallmark of aging) is coupled with reduced nuclear NAD+ level, the process of which is dependent on SIRT1. Interestingly, increasing the NAD+ level in old mice restores mitochondrial function to a youthful state, raising the opportunity to reverse aging by modulating the mitochondrial function [82]. Senescence, an irreversible cell cycle arrest, is a driving force for organismal aging. Accumulation of senescence in an adult stem cell compartment is harmful to normal stem cells for their functions in differentiation, re-entering quiescence, and self-renewal. Inflammatory cytokines secreted from senescent cells also have a systemic effect on the pro-aging process [83]. Hence, removal of senescent cells is beneficial and has been demonstrated in model animals [84]. Drugs that selectively induce death of senescent cells may serve as an appealing alternative approach. A combination of drugs (dasatinib and quercetin) collectively termed senolytics is able to eliminate senescent cells in chronologically aged and progeroid Ercc1 mice, thus improving cardiac function and delaying the pathogenic symptoms [85]. It is exciting to see how such compounds can be translated into clinical uses and evaluation of safety. Recently, rejuvenation through the exchange of “youthful” factors from young blood is being underscored for the significance [86]. It was firstly demonstrated in a parabiotic pairing of young and old mice that share their circulatory system. This heterochronic parabiosis system improves stem cell function in multiple organs including the muscle, liver, heart, spinal cord, and even brain. Components from young blood help reverse age-related decline in skeletal muscle stem cells, cardiac hypertrophy, and improve cognitive function possibly through enhanced neurogenesis [8792]. It remains largely unknown what “rejuvenation” factor(s) is responsible for such beneficial effect. Nevertheless, clinical trials using young blood have been approved for testing in people with Alzheimer’s disease and perhaps for progeroid syndromes in the future.
Fig. 2

Drugs that improve aging cells. Resveratrol and NAD+ are known to improve mitochondrial dysfunction associated with aging, whereas vitamin C is an anti-oxidant for scavenging ROS as well as its additional role in epigenetic control. SB203580 is a p38 inhibitor that prevents premature senescence. Other compounds that have been shown to improve healthy aging may also benefit progeroid cells. Senolytics are drugs that selectively remove senescent cells, whereas rapamycin and metformin increase lifespan by targeting the mTOR pathway. Unknown factors from young blood may also improve aging in various organs

Concluding remarks

Understanding the molecular mechanism driving adult stem cell aging will help us design drugs for combating aging. Progeroid syndromes are good models since the disrupted genetic pathways related to aging have been well studied. It is worth noting that biological aging is a consequence of multiple factors, each with its importance. This review only highlights the importance of telomere function and epigenetic regulation in WS because of the nature of the WRN helicase involved in these pathways. Other pathways such as ROS production, protein homeostasis, and mitochondrial dysfunction are equally important. Moreover, the aging mechanism of stem cells in different disease models does not completely overlap. The molecular mechanism leading to HGPS, for instance, is not identical to WS, although many similarities are found (e.g., epigenetic changes and accelerated senescence in mesenchymal cells). A more detailed comparison between different segmental progeroid syndromes can be found in other reviews [9, 93, 94]. To conclude, recent breakthroughs in studying age-associated diseases open new avenues to improve human health by targeting the aging pathways.

Declarations

Acknowledgements

This work was partly supported by the Lo Kwee-Seong Biomedical Research Fund and the Chinese University of Hong Kong (CUHK) Vice Chancellor (VC) Discretionary Fund.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
CUHK-CAS GIBH Joint Research Laboratory on Stem Cell and Regenerative Medicine, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
(2)
Chinese Academy of Sciences (CAS) Guangzhou Institutes of Biomedicine and Health (GIBH)
(3)
The Chinese University of Hong Kong

References

  1. Muftuoglu M, Oshima J, von Kobbe C, Cheng WH, Leistritz DF, Bohr VA. The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet. 2008;124(4):369–77. doi:10.1007/s00439-008-0562-0.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Goto M, Ishikawa Y, Sugimoto M, Furuichi Y. Werner syndrome: a changing pattern of clinical manifestations in Japan (1917~2008). Biosci Trends. 2013;7(1):13–22.PubMedGoogle Scholar
  3. Uhrhammer NA, Lafarge L, Dos Santos L, Domaszewska A, Lange M, Yang Y, et al. Werner syndrome and mutations of the WRN and LMNA genes in France. Hum Mutat. 2006;27(7):718–9. doi:10.1002/humu.9435.View ArticlePubMedGoogle Scholar
  4. Satoh M, Imai M, Sugimoto M, Goto M, Furuichi Y. Prevalence of Werner’s syndrome heterozygotes in Japan. Lancet. 1999;353(9166):1766. doi:10.1016/S0140-6736(98)05869-3.View ArticlePubMedGoogle Scholar
  5. Rossi ML, Ghosh AK, Bohr VA. Roles of Werner syndrome protein in protection of genome integrity. DNA Repair. 2010;9(3):331–44. doi:10.1016/j.dnarep.2009.12.011.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Opresko PL. Telomere ResQue and preservation--roles for the Werner syndrome protein and other RecQ helicases. Mech Ageing Dev. 2008;129(1–2):79–90. doi:10.1016/j.mad.2007.10.007.View ArticlePubMedGoogle Scholar
  7. Pichierri P, Ammazzalorso F, Bignami M, Franchitto A. The Werner syndrome protein: linking the replication checkpoint response to genome stability. Aging. 2011;3(3):311–8.PubMed CentralPubMedGoogle Scholar
  8. Salk D, Au K, Hoehn H, Martin GM. Cytogenetics of Werner’s syndrome cultured skin fibroblasts: variegated translocation mosaicism. Cytogenet Cell Genet. 1981;30(2):92–107.View ArticlePubMedGoogle Scholar
  9. Kudlow BA, Kennedy BK, Monnat Jr RJ. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol. 2007;8(5):394–404. doi:10.1038/nrm2161.View ArticlePubMedGoogle Scholar
  10. Oh J, Lee YD, Wagers AJ. Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat Med. 2014;20(8):870–80. doi:10.1038/nm.3651.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Nordfjall K, Svenson U, Norrback KF, Adolfsson R, Lenner P, Roos G. The individual blood cell telomere attrition rate is telomere length dependent. PLoS Genet. 2009;5(2), e1000375. doi:10.1371/journal.pgen.1000375.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature. 2011;469(7328):102–6. doi:10.1038/nature09603.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Diotti R, Loayza D. Shelterin complex and associated factors at human telomeres. Nucleus. 2011;2(2):119–35. doi:10.4161/nucl.2.2.15135.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Sfeir A, de Lange T. Removal of shelterin reveals the telomere end-protection problem. Science. 2012;336(6081):593–7. doi:10.1126/science.1218498.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Jones M, Osawa G, Regal JA, Weinberg DN, Taggart J, Kocak H, et al. Hematopoietic stem cells are acutely sensitive to Acd shelterin gene inactivation. J Clin Invest. 2014;124(1):353–66. doi:10.1172/JCI67871.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Flores I, Canela A, Vera E, Tejera A, Cotsarelis G, Blasco MA. The longest telomeres: a general signature of adult stem cell compartments. Genes and Dev. 2008;22(5):654–67. doi:10.1101/gad.451008.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Ishikawa N, Nakamura K, Izumiyama-Shimomura N, Aida J, Ishii A, Goto M, et al. Accelerated in vivo epidermal telomere loss in Werner syndrome. Aging. 2011;3(4):417–29.PubMed CentralPubMedGoogle Scholar
  18. Crabbe L, Jauch A, Naeger CM, Holtgreve-Grez H, Karlseder J. Telomere dysfunction as a cause of genomic instability in Werner syndrome. Proc Natl Acad Sci U S A. 2007;104(7):2205–10. doi:10.1073/pnas.0609410104.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Lombard DB, Beard C, Johnson B, Marciniak RA, Dausman J, Bronson R, et al. Mutations in the WRN gene in mice accelerate mortality in a p53-null background. Mol Cell Biol. 2000;20(9):3286–91.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Chang S, Multani AS, Cabrera NG, Naylor ML, Laud P, Lombard D, et al. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet. 2004;36(8):877–82. doi:10.1038/ng1389.View ArticlePubMedGoogle Scholar
  21. Choi D, Whittier PS, Oshima J, Funk WD. Telomerase expression prevents replicative senescence but does not fully reset mRNA expression patterns in Werner syndrome cell strains. FASEB J. 2001;15(6):1014–20.View ArticlePubMedGoogle Scholar
  22. Multani AS, Chang S. WRN at telomeres: implications for aging and cancer. J Cell Sci. 2007;120(Pt 5):713–21. doi:10.1242/jcs.03397.View ArticlePubMedGoogle Scholar
  23. Crabbe L, Verdun RE, Haggblom CI, Karlseder J. Defective telomere lagging strand synthesis in cells lacking WRN helicase activity. Science. 2004;306(5703):1951–3. doi:10.1126/science.1103619.View ArticlePubMedGoogle Scholar
  24. Cheung HH, Liu X, Canterel-Thouennon L, Li L, Edmonson C, Rennert OM. Telomerase protects Werner syndrome lineage-specific stem cells from premature aging. Stem Cell Reports. 2014;2(4):534–46. doi:10.1016/j.stemcr.2014.02.006.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer. 2007;96(7):1020–4. doi:10.1038/sj.bjc.6603671.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Shimamoto A, Kagawa H, Zensho K, Sera Y, Kazuki Y, Osaki M, et al. Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS One. 2014;9(11), e112900. doi:10.1371/journal.pone.0112900.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet. 2007;23(8):413–8. doi:10.1016/j.tig.2007.05.008.View ArticlePubMedGoogle Scholar
  28. Rando TA, Chang HY. Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. Cell. 2012;148(1–2):46–57. doi:10.1016/j.cell.2012.01.003.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Shumaker DK, Dechat T, Kohlmaier A, Adam SA, Bozovsky MR, Erdos MR, et al. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci U S A. 2006;103(23):8703–8. doi:10.1073/pnas.0602569103.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Sarg B, Koutzamani E, Helliger W, Rundquist I, Lindner HH. Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J Biol Chem. 2002;277(42):39195–201. doi:10.1074/jbc.M205166200.View ArticlePubMedGoogle Scholar
  31. Zhang W, Li J, Suzuki K, Qu J, Wang P, Zhou J, et al. Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. Science. 2015;348(6239):1160–3. doi:10.1126/science.aaa1356.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Bollati V, Schwartz J, Wright R, Litonjua A, Tarantini L, Suh H, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. Mech Ageing Dev. 2009;130(4):234–9. doi:10.1016/j.mad.2008.12.003.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, Wiemels JL, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009;5(8), e1000602. doi:10.1371/journal.pgen.1000602.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Heyn H, Moran S, Esteller M. Aberrant DNA methylation profiles in the premature aging disorders Hutchinson-Gilford Progeria and Werner syndrome. Epigenetics. 2013;8(1):28–33. doi:10.4161/epi.23366.PubMed CentralView ArticlePubMedGoogle Scholar
  35. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A. 2006;103(23):8822–7. doi:10.1073/pnas.0600645103.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Zhu X, Zhang G, Kang L, Guan H. Epigenetic regulation of Werner syndrome gene in age-related cataract. Journal of Ophthalmology. 2015
  37. Ghosh S, Zhou Z. SIRTain regulators of premature senescence and accelerated aging. Protein and Cell. 2015;6(5):322–33. doi:10.1007/s13238-015-0149-1.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, Reinberg D. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature. 2007;450(7168):440–4. doi:10.1038/nature06268.View ArticlePubMedGoogle Scholar
  39. Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3. doi:10.1038/ncomms1001.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, et al. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 2013;18(3):416–30. doi:10.1016/j.cmet.2013.07.013.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park SK, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 2008;135(5):907–18. doi:10.1016/j.cell.2008.10.025.PubMed CentralView ArticlePubMedGoogle Scholar
  42. Rimmele P, Bigarella CL, Liang R, Izac B, Dieguez-Gonzalez R, Barbet G, et al. Aging-like phenotype and defective lineage specification in SIRT1-deleted hematopoietic stem and progenitor cells. Stem Cell Reports. 2014;3(1):44–59. doi:10.1016/j.stemcr.2014.04.015.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Yuan HF, Zhai C, Yan XL, Zhao DD, Wang JX, Zeng Q, et al. SIRT1 is required for long-term growth of human mesenchymal stem cells. J Mol Med (Berl). 2012;90(4):389–400. doi:10.1007/s00109-011-0825-4.View ArticleGoogle Scholar
  44. Buhrmann C, Busch F, Shayan P, Shakibaei M. Sirtuin-1 (SIRT1) is required for promoting chondrogenic differentiation of mesenchymal stem cells. J Biol Chem. 2014;289(32):22048–62. doi:10.1074/jbc.M114.568790.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Liu B, Ghosh S, Yang X, Zheng H, Liu X, Wang Z, et al. Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metab. 2012;16(6):738–50. doi:10.1016/j.cmet.2012.11.007.View ArticlePubMedGoogle Scholar
  46. Vaitiekunaite R, Butkiewicz D, Krzesniak M, Przybylek M, Gryc A, Snietura M, et al. Expression and localization of Werner syndrome protein is modulated by SIRT1 and PML. Mech Ageing Dev. 2007;128(11–12):650–61. doi:10.1016/j.mad.2007.09.004.View ArticlePubMedGoogle Scholar
  47. Li K, Casta A, Wang R, Lozada E, Fan W, Kane S, et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. J Biol Chem. 2008;283(12):7590–8. doi:10.1074/jbc.M709707200.View ArticlePubMedGoogle Scholar
  48. Li K, Wang R, Lozada E, Fan W, Orren DK, Luo J. Acetylation of WRN protein regulates its stability by inhibiting ubiquitination. PLoS One. 2010;5(4), e10341. doi:10.1371/journal.pone.0010341.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Lee SY, Lee H, Kim ES, Park S, Lee J, Ahn B. WRN translocation from nucleolus to nucleoplasm is regulated by SIRT1 and required for DNA repair and the development of chemoresistance. Mutat Res. 2015;774:40–8. doi:10.1016/j.mrfmmm.2015.03.001.View ArticlePubMedGoogle Scholar
  50. Braidy N, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, et al. Differential expression of sirtuins in the aging rat brain. Front Cell Neurosci. 2015;9:167. doi:10.3389/fncel.2015.00167.PubMed CentralView ArticlePubMedGoogle Scholar
  51. Endisha H, Merrill-Schools J, Zhao M, Bristol M, Wang X, Kubben N, et al. Restoring SIRT6 expression in Hutchinson-Gilford progeria syndrome cells impedes premature senescence and formation of dysmorphic nuclei. Pathobiology. 2015;82(1):9–20. doi:10.1159/000368856.View ArticlePubMedGoogle Scholar
  52. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315–29. doi:10.1016/j.cell.2005.11.044.View ArticlePubMedGoogle Scholar
  53. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218–21. doi:10.1038/nature10815.View ArticlePubMedGoogle Scholar
  54. Tennen RI, Bua DJ, Wright WE, Chua KF. SIRT6 is required for maintenance of telomere position effect in human cells. Nat Commun. 2011;2:433. doi:10.1038/ncomms1443.PubMed CentralView ArticlePubMedGoogle Scholar
  55. Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;452(7186):492–6. doi:10.1038/nature06736.PubMed CentralView ArticlePubMedGoogle Scholar
  56. McCord RA, Michishita E, Hong T, Berber E, Boxer LD, Kusumoto R, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging. 2009;1(1):109–21.PubMed CentralPubMedGoogle Scholar
  57. Cherry AB, Daley GQ. Reprogramming cellular identity for regenerative medicine. Cell. 2012;148(6):1110–22. doi:10.1016/j.cell.2012.02.031.PubMed CentralView ArticlePubMedGoogle Scholar
  58. Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007;1(1):55–70. doi:10.1016/j.stem.2007.05.014.View ArticlePubMedGoogle Scholar
  59. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76. doi:10.1016/j.cell.2006.07.024.View ArticlePubMedGoogle Scholar
  60. Lapasset L, Milhavet O, Prieur A, Besnard E, Babled A, Ait-Hamou N, et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 2011;25(21):2248–53. doi:10.1101/gad.173922.111.PubMed CentralView ArticlePubMedGoogle Scholar
  61. Zhang J, Lian Q, Zhu G, Zhou F, Sui L, Tan C, et al. A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell. 2011;8(1):31–45. doi:10.1016/j.stem.2010.12.002.View ArticlePubMedGoogle Scholar
  62. Ho JC, Zhou T, Lai WH, Huang Y, Chan YC, Li X, et al. Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging. 2011;3(4):380–90.PubMed CentralPubMedGoogle Scholar
  63. Marion RM, Blasco MA. Telomere rejuvenation during nuclear reprogramming. Curr Opin Genet Dev. 2010;20(2):190–6. doi:10.1016/j.gde.2010.01.005.View ArticlePubMedGoogle Scholar
  64. Marion RM, Strati K, Li H, Tejera A, Schoeftner S, Ortega S, et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell. 2009;4(2):141–54. doi:10.1016/j.stem.2008.12.010.View ArticlePubMedGoogle Scholar
  65. Wyllie FS, Jones CJ, Skinner JW, Haughton MF, Wallis C, Wynford-Thomas D, et al. Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts. Nat Genet. 2000;24(1):16–7. doi:10.1038/71630.View ArticlePubMedGoogle Scholar
  66. Narsinh KH, Wu JC. Gene correction in human embryonic and induced pluripotent stem cells: promises and challenges ahead. Mol Ther. 2010;18(6):1061–3. doi:10.1038/mt.2010.92.PubMed CentralView ArticlePubMedGoogle Scholar
  67. Ghosh S, Thrasher AJ, Gaspar HB. Gene therapy for monogenic disorders of the bone marrow. Br J Haematol. 2015. doi:10.1111/bjh.13520.Google Scholar
  68. Huang S, Lee L, Hanson NB, Lenaerts C, Hoehn H, Poot M, et al. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat. 2006;27(6):558–67. doi:10.1002/humu.20337.PubMed CentralView ArticlePubMedGoogle Scholar
  69. Li B, Jog SP, Reddy S, Comai L. WRN controls formation of extrachromosomal telomeric circles and is required for TRF2DeltaB-mediated telomere shortening. Mol Cell Biol. 2008;28(6):1892–904. doi:10.1128/MCB.01364-07.PubMed CentralView ArticlePubMedGoogle Scholar
  70. Laud PR, Multani AS, Bailey SM, Wu L, Ma J, Kingsley C, et al. Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev. 2005;19(21):2560–70. doi:10.1101/gad.1321305.PubMed CentralView ArticlePubMedGoogle Scholar
  71. Massip L, Garand C, Paquet ER, Cogger VC, O’Reilly JN, Tworek L, et al. Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J. 2010;24(1):158–72. doi:10.1096/fj.09-137133.PubMed CentralView ArticlePubMedGoogle Scholar
  72. Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2010;6(1):71–9. doi:10.1016/j.stem.2009.12.001.View ArticlePubMedGoogle Scholar
  73. Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X, et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 2011;9(6):575–87. doi:10.1016/j.stem.2011.10.005.View ArticlePubMedGoogle Scholar
  74. Chen J, Guo L, Zhang L, Wu H, Yang J, Liu H, et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat Genet. 2013;45(12):1504–9. doi:10.1038/ng.2807.View ArticlePubMedGoogle Scholar
  75. Donadille B, D’Anella P, Auclair M, Uhrhammer N, Sorel M, Grigorescu R, et al. Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome. Orphanet J Rare Dis. 2013;8:106. doi:10.1186/1750-1172-8-106.PubMed CentralView ArticlePubMedGoogle Scholar
  76. Yasuda H, Nagata M, Hara K, Moriyama H, Yokono K. Biguanide, but not thiazolidinedione, improved insulin resistance in Werner syndrome. J Am Geriatr Soc. 2010;58(1):181–2. doi:10.1111/j.1532-5415.2009.02636.x.View ArticlePubMedGoogle Scholar
  77. Izumino K, Sakamaki H, Ishibashi M, Takino H, Yamasaki H, Yamaguchi Y, et al. Troglitazone ameliorates insulin resistance in patients with Werner’s syndrome. J Clin Endocrinol Metab. 1997;82(8):2391–5. doi:10.1210/jcem.82.8.4162.PubMedGoogle Scholar
  78. De Haes W, Frooninckx L, Van Assche R, Smolders A, Depuydt G, Billen J, et al. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc Natl Acad Sci U S A. 2014;111(24):E2501–9. doi:10.1073/pnas.1321776111.PubMed CentralView ArticlePubMedGoogle Scholar
  79. Vigili de Kreutzenberg S, Ceolotto G, Cattelan A, Pagnin E, Mazzucato M, Garagnani P et al. Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2015;25(7):686–93. doi:10.1016/j.numecd.2015.03.007.
  80. Labbe A, Garand C, Cogger VC, Paquet ER, Desbiens M, Le Couteur DG, et al. Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome. J Gerontol A Biol Sci Med Sci. 2011;66(3):264–78. doi:10.1093/gerona/glq184.View ArticlePubMedGoogle Scholar
  81. Davis T, Baird DM, Haughton MF, Jones CJ, Kipling D. Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor. J Gerontol A Biol Sci Med Sci. 2005;60(11):1386–93.View ArticlePubMedGoogle Scholar
  82. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–38. doi:10.1016/j.cell.2013.11.037.PubMed CentralView ArticlePubMedGoogle Scholar
  83. Beltrami AP, Cesselli D, Beltrami CA. Stem cell senescence and regenerative paradigms. Clin Pharmacol Ther. 2012;91(1):21–9. doi:10.1038/clpt.2011.262.View ArticlePubMedGoogle Scholar
  84. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232–6. doi:10.1038/nature10600.PubMed CentralView ArticlePubMedGoogle Scholar
  85. Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. doi:10.1111/acel.12344.Google Scholar
  86. Scudellari M. Ageing research: blood to blood. Nature. 2015;517(7535):426–9. doi:10.1038/517426a.View ArticlePubMedGoogle Scholar
  87. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433(7027):760–4. doi:10.1038/nature03260.View ArticlePubMedGoogle Scholar
  88. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90–4. doi:10.1038/nature10357.PubMed CentralView ArticlePubMedGoogle Scholar
  89. Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007;317(5839):807–10. doi:10.1126/science.1144090.View ArticlePubMedGoogle Scholar
  90. Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20(6):659–63. doi:10.1038/nm.3569.PubMed CentralView ArticlePubMedGoogle Scholar
  91. Ruckh JM, Zhao JW, Shadrach JL, van Wijngaarden P, Rao TN, Wagers AJ, et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell. 2012;10(1):96–103. doi:10.1016/j.stem.2011.11.019.PubMed CentralView ArticlePubMedGoogle Scholar
  92. Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153(4):828–39. doi:10.1016/j.cell.2013.04.015.PubMed CentralView ArticlePubMedGoogle Scholar
  93. Li B, Jog S, Candelario J, Reddy S, Comai L. Altered nuclear functions in progeroid syndromes: a paradigm for aging research. ScientificWorldJournal. 2009;9:1449–62. doi:10.1100/tsw.2009.159.PubMed CentralView ArticlePubMedGoogle Scholar
  94. Ramirez CL, Cadinanos J, Varela I, Freije JM, Lopez-Otin C. Human progeroid syndromes, aging and cancer: new genetic and epigenetic insights into old questions. Cell Mol Life Sci. 2007;64(2):155–70. doi:10.1007/s00018-006-6349-3.View ArticlePubMedGoogle Scholar

Copyright

© Cheung et al. 2015